Cardiovascular effects of coumarins besides their antioxidant activity
Language English Country United Arab Emirates Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
25697565
DOI
10.2174/1568026615666150220112437
PII: CTMC-EPUB-65323
Knihovny.cz E-resources
- MeSH
- Antioxidants pharmacokinetics pharmacology therapeutic use toxicity MeSH
- Platelet Aggregation Inhibitors pharmacokinetics pharmacology therapeutic use toxicity MeSH
- Cardiovascular Diseases blood drug therapy metabolism physiopathology MeSH
- Clinical Trials as Topic MeSH
- Coumarins pharmacokinetics pharmacology therapeutic use toxicity MeSH
- Humans MeSH
- Molecular Structure MeSH
- Drug Discovery MeSH
- Vasodilator Agents pharmacokinetics pharmacology therapeutic use toxicity MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antioxidants MeSH
- Platelet Aggregation Inhibitors MeSH
- Coumarins MeSH
- Vasodilator Agents MeSH
Coumarins are a large group of substances, primarily of plant origin. Like their more intensively examined congeners flavonoids, many of them are antioxidants. Although such properties may be advantageous in cardiovascular diseases, it has been shown that coumarins exhibit direct effects on the cardiovascular system which are not based on antioxidant activity. The most common example is the well-known drug warfarin, a synthetic compound derived from natural dicoumarol. Moreover, other coumarins have been shown to possess antiplatelet and vasodilatory potential. Interestingly, the former effect may be mediated by the inhibition of various pathways leading to platelet aggregation, their differing effects on those pathways being due to structural differences between the various coumarins. Conversely, their vasodilatory potential is linked in the majority of cases to the inhibition of increases in intracellular calcium concentration in vascular smooth muscle cells, and in several coumarins also to NO-mediated vasodilatation. Available data on both activities are summarized in this review. At the end of this review, relevant data are provided from a few studies testing the in vivo effects of coumarins on major cardiovascular diseases; the clinical use of warfarin and other coumarin anticoagulants, as well as the limited data on the clinical use of coumarins in chronic venous insufficiency and the possible toxicological effects of coumarins.
References provided by Crossref.org